文献速递浆细胞疾病

TAK1抑制可逆转TRAIL的破骨细胞生成作用并增强其抗骨髓瘤效应

TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.
PubMed 文献 · Blood Adv · 2017-10-26

本研究探讨TRAIL对骨髓瘤(MM)增强的破骨细胞生成的影响。TRAIL诱导MM细胞凋亡但不诱导破骨细胞(OC)凋亡,反而通过TAK1磷酸化形成复合物II激活NF-κB并上调c-FLIP促进破骨细胞生成。TAK1抑制剂LLZ1640-2可消除TRAIL诱导的c-FLIP上调和NF-κB活化,触发OC中caspase-8活化和细胞死亡,并在与MM细胞共培养时增强TRAIL的抗MM效应。

要点

  • TRAIL诱导MM细胞凋亡但不诱导破骨细胞凋亡,反而促进RANKL诱导的破骨细胞生成。
  • 破骨细胞中TRAIL通过TAK1磷酸化形成复合物II激活NF-κB并上调c-FLIP,不形成死亡诱导信号复合物。
  • TAK1抑制剂LLZ1640-2可逆转TRAIL的破骨细胞生成作用并增强其抗MM效应。

核心结论

  • 破骨细胞谱系细胞利用TRAIL通过将caspase-8依赖性凋亡转向NF-κB活化来促进其分化和活化。
  • TAK1抑制可逆转TRAIL介导的NF-κB活化,恢复TRAIL诱导的破骨细胞凋亡,并与TRAIL联合进一步增强MM细胞死亡。

研究设计与样本

  • 本研究为体外实验研究,探讨TRAIL对MM细胞和破骨细胞的作用及TAK1抑制的影响。

主要发现

  • TRAIL诱导MM细胞凋亡,但不诱导破骨细胞凋亡,反而促进RANKL诱导的破骨细胞生成并上调c-FLIP。
  • 破骨细胞中TRAIL未形成死亡诱导信号复合物,而是形成复合物II并磷酸化TAK1,激活NF-κB信号。
  • c-FLIP敲低消除复合物II形成,使破骨细胞对TRAIL诱导的细胞死亡敏感。
  • TAK1抑制剂LLZ1640-2消除TRAIL诱导的c-FLIP上调和NF-κB活化,触发破骨细胞中caspase-8活化和细胞死亡。
  • TRAIL诱导的caspase-8活化导致转录因子Sp1酶解,降低c-FLIP表达,进一步使破骨细胞对TRAIL诱导的凋亡敏感。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) agonists induce tumor-specific apoptosis indicating that they may be an attractive therapeutic strategy against cancers, including multiple myeloma (MM). Osteoclastogenesis is highly induced in MM, which in turn enhances MM growth, thereby forming a vicious cycle between MM tumor expansion and bone destruction. However, the effects of TRAIL on MM-enhanced osteoclastogenesis remain largely unknown. Here, we show that TRAIL induced apoptosis in MM cells, but not in osteoclasts (OCs), and that it rather facilitated receptor activator of NF-κB ligand-induced osteoclastogenesis along with upregulation of cellular FLICE inhibitory protein (c-FLIP). TRAIL did not induce death-inducing signaling complex formation in OCs, but formed secondary complex (complex II) with the phosphorylation of transforming growth factor β-activated kinase-1 (TAK1), and thus activated NF-κB signaling. c-FLIP knockdown abolished complex II formation, thus permitting TRAIL induction of OC cell death. The TAK1 inhibitor LLZ1640-2 abrogated the TRAIL-induced c-FLIP upregulation and NF-κB activation, and triggered TRAIL-induced caspase-8 activation and cell death in OCs. Interestingly, the TRAIL-induced caspase-8 activation caused enzymatic degradation of the transcription factor Sp1 to noticeably reduce c-FLIP expression, which further sensitized OCs to TRAIL-induced apoptosis. Furthermore, the TAK1 inhibition induced antiosteoclastogenic activity by TRAIL even in cocultures with MM cells while potentiating TRAIL's anti-MM effects. These results demonstrated that osteoclastic lineage cells use TRAIL for their differentiation and activation through tilting caspase-8-dependent apoptosis toward NF-κB activation, and that TAK1 inhibition subverts TRAIL-mediated NF-κB activation to resume TRAIL-induced apoptosis in OCs while further enhancing MM cell death in combination with TRAIL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tenshin H, Teramachi J, Oda A, et al. TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects. Blood Adv. 2017. PMID: 29296860. doi:10.1182/bloodadvances.2017008813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。